Chemical structure and therapeutic applications of obeticholic acid

Obeticholic acid (Obeticholic acid) is a farnesoid X receptor (FXR) agonist with significant pharmacological activity. Its chemical structure is unique and is 3α,7α-dihydroxy-6α-ethyl-5β-cholestane-24-acid. This substance appears as a white to off-white powder and has good solubility, especially in organic solvents such as methanol, acetone and ethyl acetate. Its solubility in water is affected by pH value. It is slightly soluble at low pH, but more soluble in high pH environment. Its precise chemical formula is C26H44O4, and its precise molecular weight is 420.63g/mol.

In medical applications, obeticholic acid tablets are mainly available in two oral dosage specifications: 5mg and 10mg. In addition to the main active ingredient obeticholic acid, the tablets also contain inactive ingredients such as microcrystalline cellulose, sodium starch glycolate, and magnesium stearate. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to obeticholic acid for the treatment of primary biliary cholangitis, a chronic cholestatic disease. Obeticholic acid can be combined with ursodeoxycholic acid (UDCA) to enhance therapeutic effects. FXR, as a nuclear receptor widely expressed in the liver and intestine, plays a key regulatory role in bile acid metabolism, inflammatory response, fibrosis process and metabolic pathways.

When using obeticholic acid, patients need to be aware of possible side effects, the most common of which are itching and fatigue. During treatment, doctors will regularly monitor the patient's biochemical indicators to assess drug tolerance, disease progression, and whether drug discontinuation is needed. In addition, because obeticholic acid may affect blood lipid concentrations, especially for patients who use cholic acid to reduce high-density lipoprotein cholesterol concentrations, doctors will evaluate the patient's response after 1 year of treatment to decide whether to continue treatment.